Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report. - Manabe K; Shien K; Furukawa S; Seno T; Ishimura K; Tanaka S; Suzawa K; Okazaki M; Sugimoto S; Toyooka S (BMC pulmonary medicine, 2025)